AstraZeneca PLC (NASDAQ:AZN) Q2 2025 Earnings Convention Name July 29, 2025 9:00 AM ET
Firm Contributors
Andrew P. Barnett – Head of Investor Relations
Aradhana Sarin – CFO & Government Director
David Fredrickson – Government Vice-President of Oncology Haematology Enterprise Unit
Iskra Reic – Government Vice President of Worldwide
Marc Dunoyer – CEO of Alexion & Chief Technique Officer
Pascal Claude Roland Soriot – CEO & Government Director
Ruud Dobber – Government Vice-President of BioPharmaceuticals Enterprise Unit
Sharon Barr – Government Vice-President of BioPharmaceuticals R&D
Susan Mary Galbraith – Government Vice President of Oncology R&D
Convention Name Contributors
Gonzalo Artiach Castanon – Danske Financial institution A/S, Analysis Division
James Daniel Gordon – JPMorgan Chase & Co, Analysis Division
Luisa Caroline Hector – Joh. Berenberg, Gossler & Co. KG, Analysis Division
Matthew Weston – UBS Funding Financial institution, Analysis Division
Michael Leuchten – Unidentified Firm
Peter Verdult – BNP Paribas Exane, Analysis Division
Rajan Sharma – Goldman Sachs Group, Inc., Analysis Division
Sachin Jain – BofA Securities, Analysis Division
Sarita Kapila – Morgan Stanley, Analysis Division
Seamus Christopher Fernandez – Guggenheim Securities, LLC, Analysis Division
Operator
Good afternoon, and welcome to AstraZeneca’s H1 and Q2 2025 webinar for buyers and analysts. Earlier than I hand over to AstraZeneca, I would prefer to learn the protected harbor assertion. The corporate intends to make the most of the protected harbor provisions of the US Personal Securities Litigation Reform Act of 1995. Contributors on this name might make forward-looking statements with respect to the operations and monetary efficiency of AstraZeneca. Though we imagine our expectations are primarily based on affordable assumptions, by their very nature, forward-looking statements contain dangers and uncertainties and could also be influenced by components that might trigger precise outcomes to vary materially from these expressed or implied by these forward-looking statements.
Any forward-looking statements made on this name